Trade Report: Today, Sangamo BioSciences Inc. (SGMO) Short Interest Update

Today, Sangamo BioSciences Inc. (SGMO) Short Interest Update

Sangamo BioSciences Inc. (NASDAQ:SGMO) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 7,636,100 shares, a decrease of 12.2% from the August 31st total of 8,693,947 shares. Currently, 11.1% of the company’s shares are sold short. Based on an average daily volume of 1,017,285 shares, the days-to-cover ratio is currently 7.5 days.

SGMO has been the subject of a number of research analyst reports. Janney Montgomery Scott downgraded shares of Sangamo BioSciences from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $15.00 to $8.00 in a research report on Thursday, August 4th. Jefferies Group reissued a “buy” rating and set a $14.00 target price on shares of Sangamo BioSciences in a research report on Thursday, June 9th. Cowen and Company reissued a “buy” rating on shares of Sangamo BioSciences in a research report on Wednesday, August 10th. Finally, Zacks Investment Research downgraded shares of Sangamo BioSciences from a “hold” rating to a “sell” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $15.30.

A number of large investors have recently made changes to their positions in SGMO. Foresite Capital Management III LLC acquired a new stake in shares of Sangamo BioSciences during the first quarter worth approximately $3,296,000. Prudential Financial Inc. acquired a new stake in shares of Sangamo BioSciences during the first quarter worth approximately $1,384,000. Royce & Associates LP raised its stake in shares of Sangamo BioSciences by 46.1% in the first quarter. Royce & Associates LP now owns 456,100 shares of the biopharmaceutical company’s stock worth $2,759,000 after buying an additional 144,000 shares during the last quarter. Cannell Peter B & Co Inc raised its stake in shares of Sangamo BioSciences by 217.5% in the first quarter. Cannell Peter B & Co Inc now owns 31,750 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 21,750 shares during the last quarter. Finally, Spark Investment Management LLC acquired a new stake in shares of Sangamo BioSciences during the first quarter worth approximately $472,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Shares of Sangamo BioSciences (NASDAQ:SGMO) opened at 4.74 on Thursday. The firm’s market cap is $334.73 million. Sangamo BioSciences has a 52-week low of $4.08 and a 52-week high of $9.91. The stock’s 50 day moving average is $4.55 and its 200-day moving average is $5.70.

Sangamo BioSciences (NASDAQ:SGMO) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.14. Sangamo BioSciences had a negative return on equity of 36.08% and a negative net margin of 261.81%. The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.38 million. During the same quarter in the previous year, the business posted ($0.17) earnings per share. The company’s revenue was down 56.0% compared to the same quarter last year. Equities analysts anticipate that Sangamo BioSciences will post ($1.11) earnings per share for the current fiscal year.

About Sangamo BioSciences

Related posts

Leave a Comment